Article info

Download PDFPDF
Letter
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

Authors

  • Nevin John Neuroinflammation, University College London Institute of Neurology, London, UK PubMed articlesGoogle scholar articles
  • Antonia Carroll University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK PubMed articlesGoogle scholar articles
  • Wallace J Brownlee University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, London, UK PubMed articlesGoogle scholar articles
  • Jeremy Chataway Neuroinflammation, University College London Institute of Neurology, London, UK University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Nevin John, Neuroinflammation, UCL Institute of Neurology, London WC1N 3BG, UK; nevin.john{at}ucl.ac.uk
View Full Text

Citation

John N, Carroll A, Brownlee WJ, et al
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

Publication history

  • Received February 22, 2019
  • Revised April 15, 2019
  • Accepted April 16, 2019
  • First published May 11, 2019.
Online issue publication 
November 14, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.